Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Finer

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
European Journal of Internal Medicine|May 24, 2021
Future directions in obesity pharmacotherapyNick Finer
Diabetes, Obesity & Metabolism|October 8, 2021
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomesNick Finer
Asia Pacific Journal of Clinical Nutrition|August 25, 2006
Emerging pharmacotherapy for treating obesity and associated cardiometabolic riskIan D Caterson, Nick Finer
Obesity Research & Clinical Practice|December 20, 2013
The clinical effectiveness of weight loss drugsGary Wittert, Ian Caterson, Nick Finer
Obesity Research & Clinical Practice|December 19, 2013
Obesity remains under diagnosed in English hospital in-patientsVishwamitra Sharma, Antonia Braithwaite, Simon Harger, et al.
Obesity Surgery|December 13, 2007
The comparative effects of bariatric surgery on weight and type 2 diabetesPierre Levy, Martin Fried, Ferruccio Santini, et al.
Eating Behaviors|March 6, 2004
The Eating Disorder Inventory in a UK National Health Service Obesity Clinic and its response to modest weight lossIra C Packianathan, Maleyca Sheikh, Sarah Feben, et al.
Obesity Facts|August 25, 2016
Obesity Management in Europe: Current Status and Objectives for the FutureMagdalena F Uerlich, Volkan Yumuk, Nick Finer, et al.
Journal of Hypertension|March 14, 2014
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesityJens Jordan, Arne Astrup, Stefan Engeli, et al.
Lancet (London, England)|November 14, 2006
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled studyAndré J Scheen, Nick Finer, Priscilla Hollander, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
European Journal of Internal Medicine|May 24, 2021
Future directions in obesity pharmacotherapyNick Finer
Diabetes, Obesity & Metabolism|October 8, 2021
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomesNick Finer
Asia Pacific Journal of Clinical Nutrition|August 25, 2006
Emerging pharmacotherapy for treating obesity and associated cardiometabolic riskIan D Caterson, Nick Finer
Obesity Research & Clinical Practice|December 20, 2013
The clinical effectiveness of weight loss drugsGary Wittert, Ian Caterson, Nick Finer
Obesity Research & Clinical Practice|December 19, 2013
Obesity remains under diagnosed in English hospital in-patientsVishwamitra Sharma, Antonia Braithwaite, Simon Harger, et al.
Obesity Surgery|December 13, 2007
The comparative effects of bariatric surgery on weight and type 2 diabetesPierre Levy, Martin Fried, Ferruccio Santini, et al.
Eating Behaviors|March 6, 2004
The Eating Disorder Inventory in a UK National Health Service Obesity Clinic and its response to modest weight lossIra C Packianathan, Maleyca Sheikh, Sarah Feben, et al.
Obesity Facts|August 25, 2016
Obesity Management in Europe: Current Status and Objectives for the FutureMagdalena F Uerlich, Volkan Yumuk, Nick Finer, et al.
Journal of Hypertension|March 14, 2014
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesityJens Jordan, Arne Astrup, Stefan Engeli, et al.
Lancet (London, England)|November 14, 2006
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled studyAndré J Scheen, Nick Finer, Priscilla Hollander, et al.
Pageof 5